September 13, 2026Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026Read article
September 10, 2026Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of DirectorsRead article